3月28日上午,君实生物(01877.HK、688180.SH)港股股价盘中涨幅一度超过11%,公司前一晚发布的2024年业绩报显示,净利润亏损明显收窄。 2024年,公司实现营业收入19.48亿元,同比增长29.67%;归属于上市公司股东的净利润亏损12.81亿元,同比亏损收窄约44%,这主要得益于核心产品PD-1单抗拓益国内销售贡献以及公司对费用的控制等。 截至报告期末,君实生物已拥有特瑞...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.